Product image of Lipertance (Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate) supplied by GNH India

Lipertance

Active Ingredient:
Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate
Origin:
EU

Lipertance (Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate)

Amlodipine besilate, Perindopril arginine and Atorvastatin calcium trihydrate, the active ingredients in Lipertance, are a combination of a calcium channel blocker, an ACE inhibitor and an HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats hypertension and hyperlipidaemia, and is used to reduce cardiovascular risk in adults who need simultaneous blood‑pressure and cholesterol control.

GNH India supplies Lipertance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Servier Benelux S.A./N.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lipertance combines antihypertensive and lipid‑lowering mechanisms to manage cardiovascular risk.

  • Hypertension: lowers systolic and diastolic blood pressure, improving vascular tone and reducing the workload on the heart.
  • Hyperlipidaemia: decreases low‑density lipoprotein (LDL) cholesterol and total cholesterol, helping to achieve lipid‑profile targets.
  • Cardiovascular risk reduction: lowers the incidence of major adverse cardiac events in patients with combined hypertension and dyslipidaemia.

How It Works

  • Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, causing vasodilation; Perindopril arginine inhibits angiotensin‑converting enzyme, reducing angiotensin II formation and further promoting vasodilation; Atorvastatin calcium trihydrate inhibits HMG‑CoA reductase, decreasing hepatic cholesterol synthesis and increasing LDL‑receptor expression, which together lower blood pressure and plasma LDL‑cholesterol.

Side Effects

Lipertance may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Headache: mild to moderate headache.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness: light‑headedness, especially on standing.
  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
  • Cough: dry or productive cough.
  • Fatigue: feeling unusually tired.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of face, lips, tongue or airway.
  • Hepatotoxicity: elevated liver enzymes or jaundice.
  • Rhabdomyolysis: muscle pain with dark urine indicating severe muscle breakdown.

Precautions & Warnings

Before prescribing Lipertance, clinicians should consider several safety measures.

  • Blood pressure monitoring: check blood pressure regularly after initiating therapy.
  • Liver function assessment: evaluate hepatic enzymes before and during treatment.
  • Renal function evaluation: adjust use in patients with impaired kidney function.
  • Concomitant drug review: avoid use with strong CYP3A4 inhibitors without supervision.
  • Pregnancy and lactation: contraindicated unless benefits outweigh risks; consult a healthcare provider.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Lipertance can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Dual ACE inhibitor or ARB therapy: may cause excessive hypotension or renal impairment.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase atorvastatin levels, raising risk of myopathy.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) with perindopril: heightened risk of kidney injury.

Moderate Interactions (Monitor Closely)

  • Simvastatin or lovastatin: combined with atorvastatin may increase statin‑related toxicity.
  • Diuretics: may enhance antihypertensive effect, requiring blood‑pressure monitoring.
  • Calcium‑channel blocker combinations: additive vasodilatory effect may cause dizziness.

Frequently Asked Questions

Lipertance is a prescription oral tablet that combines three agents to treat hypertension, hyperlipidaemia, and to lower overall cardiovascular risk in adult patients who require both blood‑pressure control and cholesterol management.

Amlodipine relaxes vascular smooth muscle by blocking calcium channels, perindopril reduces angiotensin‑II production through ACE inhibition, and atorvastatin blocks HMG‑CoA reductase, decreasing hepatic cholesterol synthesis. Together they lower blood pressure and LDL‑cholesterol, addressing two major contributors to cardiovascular disease.

The appropriate dose of Lipertance is determined by the prescribing clinician based on the patient’s individual medical condition, response to therapy, and any concomitant medications. Specific dosing information should be obtained from the prescribing healthcare professional.

Safety data for Lipertance in pregnancy and lactation are limited. Generally, the components are avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lipertance, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lipertance offers a fixed‑dose combination of a calcium‑channel blocker, an ACE inhibitor and a statin, which can simplify regimens compared with taking separate agents. This may improve adherence, but clinicians must consider individual drug tolerability, potential interactions, and whether dose flexibility is needed compared with separate monotherapy options.

Lipertance should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Lipertance is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a full glass of water; do not crush, split, or chew unless specifically instructed.

Serious risks include angio‑edema, which can cause rapid swelling of the face or airway, hepatotoxicity indicated by elevated liver enzymes or jaundice, and rhabdomyolysis presenting as severe muscle pain with dark urine. Patients should seek immediate medical attention if any of these symptoms occur.

Lipertance should be avoided in patients with known hypersensitivity to any of its components, those with severe hepatic impairment, or individuals who have experienced angio‑edema with ACE inhibitors. It is also contraindicated in patients where the risks of combined antihypertensive and statin therapy outweigh the benefits, as determined by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Amlodipine Besilate, Perindopril Arginine, Atorvastatin Calcium Trihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT